Eli Lilly Rises Over 3% Pre-Market as China Approval of First Oral GLP-1 Weight-Loss Drug Pushes LLY Toward Record High
TradingKey - Eli Lilly (LLY) rose more than 3% in US premarket trading on Thursday, with shares climbing to around $1,488. If this rally holds into the regular session, the stock is poised to set an all-time high. The key driver boosting market sentiment is that Eli Lilly's oral GLP-1 weight-loss drug, orforglipron calcium tablets, officially received approval from China's National Medical Products Administration under the brand name "Muyouda".
Source: TradingView
The approval makes Muyouda the first oral GLP-1 drug approved for weight management in China, signaling that the domestic weight-loss treatment market is transitioning from being dominated by injectables to a new phase of side-by-side competition between oral and injectable products. The drug is indicated as an adjunct to diet and exercise for long-term weight management in adults with obesity, or overweight adults with related health conditions.
Compared with weekly injectable GLP-1 products, the oral formulation lowers the barrier to use for some patients and is particularly expected to appeal to those resistant to injections. In addition, Muyouda offers the flexibility of being taken with or without food, requires no refrigeration, and has a small-molecule structure that makes scaled manufacturing easier—features that could help Eli Lilly expand the reach of its weight-loss therapies.
Muyouda was previously approved by the U.S. Food and Drug Administration in April 2026 under the overseas brand name Foundayo. Entering the Chinese market, the product will compete with Eli Lilly's own once-weekly weight-loss injectables, as well as similar products from companies such as Novo Nordisk (NVO), Pfizer (PFE), and Innovent Biologics.
Novo Nordisk has also submitted a marketing application in China for an oral version of Wegovy, so Eli Lilly's first-mover approval provides it with a time advantage in securing prescription patients and distribution channels.
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Recommended Articles
